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Optimal treatment of Alzheimer’s disease 
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Blaine S Greenwald2
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NY, USA; 2Zucker Hillside Hospital, 
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Abstract: Psychotic symptoms emerging in the context of neurodegeneration as a consequence 
of Alzheimer’s disease was recognized and documented by Alois Alzheimer himself in his 
description of the first reported case of the disease. Over a quarter of a century ago, in the context 
of attempting to develop prognostic markers of disease progression, psychosis was identified as 
an independent predictor of a more-rapid cognitive decline. This finding has been subsequently 
well replicated, rendering psychotic symptoms an important area of exploration in clinical his-
tory taking – above and beyond treatment necessity – as their presence has prognostic signifi-
cance. Further, there is now a rapidly accreting body of research that suggests that psychosis 
in Alzheimer’s disease (AD+P) is a heritable disease subtype that enjoys neuropathological 
specificity and localization. There is now hope that the elucidation of the neurobiology of the 
syndrome will pave the way to translational research eventuating in new treatments. To date, 
however, the primary treatments employed in alleviating the suffering caused by AD+P are the 
atypical antipsychotics. These agents are approved by the US Food and Drug Administration for 
the treatment of schizophrenia, but they have only marginal efficacy in treating AD+P and are 
associated with troubling levels of morbidity and mortality. For clinical approaches to AD+P 
to be optimized, this syndrome must be disentangled from other primary psychotic disorders, 
and recent scientific advances must be translated into disease-specific therapeutic interventions. 
Here we provide a review of atypical antipsychotic efficacy in AD+P, followed by an overview 
of critical neurobiological observations that point towards a frontal, tau-mediated model of 
disease, and we suggest a new preclinical animal model for future translational research.
Keywords: Alzheimer’s disease, antipsychotics, psychosis, tau, behavioral disturbance, agitation
Introduction
There is urgency to the problem of the need for efficacious drug treatment in the 
management of Alzheimer’s disease with psychosis (AD+P). AD+P has grave con-
sequence, particularly for caregivers, as it is associated with physical aggression, and 
caregivers are most often the victims.1–3 Violent behavior that is directed towards 
caregivers is disruptive of care at the very least, but can also be dangerous for those 
charged with providing a safe environment for those suffering with disease. Not only 
is aggressive behavior inherently troublesome for families, but perhaps in part because 
of the difficulty of managing these behaviors, the rates of institutionalization are much 
higher in AD patients who have exhibited violent behavior.4,5 Notably, in one study 
of participants with elevated levels of physical aggression, 80% had delusions.6 This 
suggests that psychosis at least aggravates the clinical course of AD, and creates 
profound caregiver stress that compounds the difficulty of taking care of a loved one 
with the cognitive impairment that is a defining feature of the illness.
Unfortunately, the current treatment approaches to AD+P, relying mostly on 
agents approved for the treatment of schizophrenia, have been largely disappointing. 
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The efficacy of the atypical antipsychotics in the treatment 
of behavioral and psychological symptoms of dementia – 
derived from randomized placebo-controlled trials – has 
been parsed many ways, owing in part to the broad range of 
rating scales employed as outcome measures and the spec-
trum of neurobehavioral syndromes associated with AD. 
Indeed, trials that have enrolled over 5,000 patients to date 
have included a number of different psychometric scales 
of behavioral impairment, including the Neuropsychiatric 
Inventory (NPI); the Brief Psychiatric Rating Scale (BPRS); 
the Cohen-Mansfield Agitation Inventory; the Clinical Global 
Impression of Change; the Clinical Global Impression of 
Severity; and the Behavioral Pathology in Alzheimer’s 
Disease (BEHAVE-AD). Evaluating the efficacy of currently 
available treatments in AD+P is challenging, as the only 
available data comprises subscales distilled from compre-
hensive agitation inventories.
The most recent and most comprehensive meta-analysis 
to date of randomized placebo-controlled trials in the treat-
ment of the behavioral and psychological symptoms of 
dementia7 suggests a consistent superiority of atypical agents 
(aripiprazole, quetiapine, olanzapine, risperidone) over 
placebo as measured with the aforementioned behavioral 
rating scales. In fact, when atypical agents are amalgamated 
and their efficacy data is compared with placebo, the most 
recent meta-analysis reveals that antipsychotics demonstrate 
a convincing superiority over placebo in the treatment of 
behavioral disturbances. Calculated mean differences and 
95% confidence intervals on behavioral rating scales sup-
port this contention: BPRS, -1.58 (-2.52 to -0.65); Cohen-
Mansfield Agitation Inventory, -1.84 (-3.01 to -0.61); 
NPI, -2.81 (-4.35 to -1.28); Clinical Global Impression of 
Change, -0.32 (-0.44 to -0.20); Clinical Global Impression 
of Severity, -0.19 (-0.3 to -0.09). These data, especially in 
light of the BPRS differences, could be taken as evidence 
that atypical antipsychotics are efficacious in the treatment 
of AD+P. 
A careful look at these studies, however, suggests the 
ironic truth that amongst therapies for behavioral distur-
bances in AD, the atypical antipsychotics are inconsistent 
at best in the treatment of psychosis. Positive results from 
the above referenced meta-analytic data on BPRS total score 
outcomes do not necessarily reflect improvement in psycho-
sis. The BPRS, (Overall and Gorham 1962, Psychological 
Report)8 an inventory of psychopathology that has been 
extensively utilized in the evaluation of outcomes in schizo-
phrenia and other psychotic illnesses, is a remarkably broad 
18-item scale.9 Only a few items could be interpreted with any 
relevance in AD+P: hostility, suspiciousness, hallucinatory 
behavior, and perhaps unusual thought content and unco-
operativeness. Although not included in the most recent 
meta-analysis, data on psychosis can be extracted from the 
majority of placebo-controlled clinical trials of antipsychotics 
in dementia populations by looking at psychosis subscores 
derived from the NPI, the BEHAVE-AD, and the BPRS 
(Table 1). Olanzapine has been evaluated in comparison 
with placebo over 6–36 weeks in nursing home patients 
and outpatients.10–12 In the first study, olanzapine at a dose 
of 5 mg and 10 mg, but not 15 mg, was superior to placebo 
on the psychosis subscale total score derived from the nurs-
ing home version of the NPI, the NPI-NH (Table 1).10 In a 
second study of 1.0 mg, 2.5 mg, 5.0 mg, and 7.5 mg doses 
of olanzapine, only the 7.5 mg dose was superior to placebo 
as measured by the NPI-NH psychosis subscale.11 In the 
Clinical Antipsychotics Trials of Intervention Effectiveness-
Alzheimer’s Disease (CATIE-AD) study, an outpatient 
study comparing flexible doses of atypical antipsychotics 
(olanzapine, quetiapine, risperidone) to placebo, olanzapine 
at a mean dose of 5.5 mg was not superior to placebo on the 
psychosis factor of the BPRS.12 Two 10-week randomized 
placebo-controlled trials have investigated aripiprazole in 
the treatment of AD+P.13,14 In the first study, an outpatient 
study employing a flexible dose, aripiprazole at a mean dose 
of 10 mg demonstrated superiority to placebo on the BPRS 
psychosis subscale but not on the NPI psychosis subscale.13 
In a nursing home study, comparing aripiprazole at doses of 
2 mg, 5 mg, and 10 mg, only 10 mg was superior to placebo 
on the NPI-NH psychosis subscale.14 Two studies, of 6 weeks 
and 36 weeks duration in nursing facilities and outpatient 
populations, respectively, have evaluated the efficacy of 
quetiapine in comparison with placebo for the treatment of 
AD+P.12,15 No evidence of efficacy in treating psychosis was 
generated for quetiapine from either study on the basis of the 
BPRS psychosis subscales. Prior to CATIE-AD, there were 
four randomized placebo-controlled trials of risperidone in 
AD+P, ranging from 8–36 weeks in both the nursing home 
residents and outpatients.16–19 A meta-analysis of these four 
studies revealed that risperidone was superior to placebo on 
the BEHAVE-AD psychosis subscale, with an effect size of 
0.154 (95% confidence interval 0.038–0.269), suggesting 
only a modest effect of drug treatment.20 Data from CAT-
IE-AD also evidenced a benefit of risperidone over placebo 
on the BPRS psychosis factor, the only agent to beat placebo 
on this measure.12 The data on atypical antipsychotics, while 
inconsistent, do suggest some utility for most agents, with 
some superiority for risperidone; however, the magnitudes of 
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treatment effects are not robust, and highly efficacious agents 
are desperately needed. One solution to this problem is to 
develop novel treatments based on the emerging neurobiol-
ogy of AD+P, rather than relying on existing treatments for 
other psychotic conditions.
Phenomenology in AD+P: 
theoretical considerations
Psychotic symptoms in AD comprise delusions, with a 
reported prevalence of between 30%–40%,21–24 and, to 
a smaller extent, hallucinations, with a prevalence of 
5%–20%.21,23,25–27 The heritability of AD+P has been firmly 
established28 and is estimated to be between 30%–60%.29 The 
persistence of untreated psychosis over time in Alzheimer’s 
disease in individual patients has not been firmly estab-
lished, but available evidence suggests that approximately 
40%–50% of psychotic individuals will continue to mani-
fest psychotic symptoms after 1 year.30 Rather than the 
bizarre delusions and complex network of unsubstantiated 
belief systems commonly seen in schizophrenia typified 
by logical impossibility and experiences alien to “ordinary 
life situations,”31 the delusions in AD+P generally involve 
rather narrow elaborations and distortions of actual experi-
ence. The delusions of AD have been largely reconciled 
into two categories,32,33 delusions of persecution (eg, theft, 
harm, jealousy, abandonment)2,34–36 and delusions of mis-
identification (eg, phantom boarder, television images are 
animate, Capgras syndrome, house is not one’s home),2,35–38 
the latter having once been conceptualized as representing 
perceptual abnormalities, but actually representing ideational 
fixations.32,39,40 A category of “autobiographical delusions,”32 
for instance that a dead relative is still alive, has also been 
suggested,41 but these may be regarded as an extension of 
the misidentification domain.
A few theoretical models have been developed to explain 
the common emergence of psychosis in AD – particularly 
focused on delusions – in those otherwise not afflicted with 
mental illness. Carefully reviewed by Reeves et al32 the earli-
est of these ratiocinations suggested that psychosis results 
from a “logical attempt to understand the environment” in 
the context of degraded cognitive integrity.42 For instance, 
the common delusions in AD – theft, jealousy, misidentifica-
tion, abandonment, phantom boarder, television images are 
animate21,43,44 – are possible narrative confabulations that fill 
in the gaps or normalize the experiences of those confronted 
with a history they have become unmoored from, and who 
rely on a gradually eroding apparatus for discriminating 
object from representation. The most intuitive support for 
Table 1 Randomized placebo-controlled trials of atypical antipsychotics in the treatment of Alzheimer’s disease with psychosis
Study Agent N Outcome measure Outcome
Street et al10 Olanzapine 5 mg, 10 mg 
versus placebo
206 NPi psychosis subscale 5 mg and 10 mg superior to placebo, 
15 mg not superior to placebo
De Deyn et al11 Olanzapine 1.0 mg, 2.5 mg, 
5.0 mg, 7.5 mg versus 
placebo
652 NPi psychosis subscale 7.5 mg superior to placebo; 1.0 mg, 
2.5 mg, 5.0 mg not superior to placebo
De Deyn et al13 Aripiprazole versus placebo 208 BPRS psychosis subscale; 
NPi psychosis subscale
Mean dose 10 mg superior to placebo 
on BPRS psychosis subscale but not NPi 
psychosis subscale
Mintzer et al14 Aripiprazole 2 mg, 5 mg, 
10 mg versus placebo
487 NPi psychosis subscale 10 mg superior to placebo, 2 mg, 5 mg 
not superior to placebo
Tariot et al15 Quetiapine versus 
haloperidol versus placebo
284 BPRS thought disturbance Mean dose 96.9 mg quetiapine, 1.9 mg 
haloperidol, neither superior to placebo
Katz et al20
Katz et al16
De Deyn et al17
Brodaty et al18
Mintzer et al19
Risperidone vs placebo 941 Meta-analysis of BeHAve-
AD psychosis subscale
Mean dose 1.09 mg risperidone 
superior to placebo, effect size 0.154 
(range 95% Ci, 0.038–0.269)
Sultzer et al12 Olanzapine versus 
quetiapine versus 
risperidone versus placebo
421 BPRS psychosis subscale; 
hostile suspiciousness factor
Mean dose olanzapine 5.5 mg superior 
to placebo on hostile suspiciousness 
but not psychosis subscale; 56.5 mg 
quetiapine not superior to placebo; 
risperidone 1 mg superior to placebo 
on both psychosis and hostile 
suspiciousness subscale
Abbreviations: BeHAve-AD, Behavioral Pathology in Alzheimer’s Disease scale; BPRS, Brief Psychiatric Rating Scale; N, number; NPi, Neuropsychiatric inventory; Ci, 
confidence interval.
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this model comes from the most prevalent delusion in AD, 
that people are hiding or stealing things,45–47 a potential 
confabulation that is entirely consistent with the primary 
cognitive deficit in AD, accelerated forgetting. Alternatively, 
some have suggested that brain disease results in “release 
symptomatology”48 or that cognitive deficits germinate 
delusional ideas as a consequence of a “lack of corrective 
judgment” from other cortical structures.49 These conceptual-
izations, while interesting, are broad and speculative and do 
not really generate any testable scientific predictions. More 
recent work has been focused on concrete neurobiological 
correlates of psychotic AD, and from that a glimpse of disease 
pathophysiology has begun to emerge.
Cognitive course and mortality 
in AD+P: evidence for a distinct 
syndrome?
The earliest specific reference to the problem of psychosis 
in the modern literature on Alzheimer’s disease emerges in 
a Russian neuropsychiatric journal in 1964.50 It was another 
20 years before critical observations were made that con-
tributed to a reconceptualization of psychotic phenomena as 
expressions of a unique pathophysiological syndrome rather 
than a mere behavioral nuisance. In the context of searching 
for clinical signs that would predict the velocity of decline 
in AD, psychosis – in addition to myoclonus and extrapy-
ramidal signs – was found to be an early marker heralding 
a hastened deterioration.51,52 This observation was quickly 
replicated in several studies reinforcing the prognostic value 
of psychosis in relationship to decline.53,54 Studies focused on 
the exploration of risk factors for psychotic symptoms in AD 
have also consistently identified a greater burden of cogni-
tive impairment as an independent risk factor for psychosis, 
with acceleration of decline emerging prior to the onset of 
psychosis.24,46,55,56
The features of accelerated cognitive impairment in 
AD+P suggest some degree of frontal localization. In one 
study of AD+P and Alzheimer’s disease without psychosis 
(AD-P) that compared subjects of similar duration of ill-
ness, age, and education, AD+P subjects evidenced more 
impairment on tasks of frontal-lobe function, including the 
Wisconsin Card Sorting Test and the similarities subtest 
of the Wechsler Adult Intelligence Scale.57 Recent studies 
suggest that working memory performance, a test of frontal 
function depending largely on the dorsolateral prefrontal 
cortex, enjoys a unique association with psychosis in AD. 
Early evidence for this emerged from an epidemiological 
study of AD+P risk factors, wherein performance on the 
digit span, a task of working memory, was observed to be a 
robust predictor of future psychosis in AD.24 Impressively, a 
one-standard-deviation improvement in this task reduced the 
risk of developing hallucinations or delusions by two thirds. 
In our own study of cognition in AD+P, we evaluated AD 
and performed stepwise regression of cognitive domains in 
order to determine whether any cognitive domains (memory, 
executive function, language) predicted psychosis. We found 
that of the wide spectrum of domains of cognition interro-
gated in the analysis, only working memory interacted with 
psychosis.58
In order to replicate the finding and to determine whether 
working memory, beyond its mere association with the state 
of psychosis, might track uniquely with the accelerated 
decline in AD+P, we performed an analysis of cognitive 
data from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) study database. The ADNI database includes lon-
gitudinal cognitive data on subjects some of whom destined 
to become psychotic, as evidenced by psychometric ratings, 
over the course of the study. We hypothesized that digit-span 
performance, amongst available cognitive metrics, would 
decline more rapidly over time as a marker of the accelerated 
decline of AD+P. Results of the analysis demonstrated that 
digit-span performance is one of only two cognitive measures 
that decline more rapidly in AD+P when compared with 
AD-P.59 It is not clear how impairment in working memory 
is etiologically related to AD+P. One possibility is that it is 
merely a byproduct of frontal degeneration, and not directly 
etiologically related; another is that accelerated frontal 
degeneration engenders working memory deficits, and that 
failures in working memory impair successful environmental 
surveillance in AD, culminating in misinterpretations and 
psychosis.
Evidence of a more aggressive cognitive phenotype as a 
marker of virulence would predict an acceleration of overall 
decline and decreased survival rates in those with AD+P. It is 
puzzling, given the established relationship between rate of 
cognitive decline and mortality in AD,60,61 that most,53,60–65 
but not all,66 early studies did not find an increased mortality 
rate in AD+P. More recent studies, with larger sample sizes 
and an enhanced follow-up with a more powerful statistical 
approach (Cox proportional hazard regression analysis) have 
consistently observed the predictive value of psychosis in 
AD survival.67–70
A parsimonious hypothesis that explains the accelerated 
cognitive deterioration with some specificity and the early 
demise of patients with AD+P is that psychosis is a behavioral 
expression of a more-rapid neurodegenerative process that 
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2257
Treatment of psychosis in Alzheimer’s disease
may be regional. If so, what regions are implicated? What 
are the neurochemical and neuropathological hallmarks 
of this distinct AD syndrome? Can answers to these ques-
tions point the way forward in developing new anti-AD+P 
treatments?
Imaging correlates in AD+P: a 
predominance of frontal localization
In the search for cerebral localization of deficit patterns in 
AD+P, investigators have, with varying levels of success 
related to sample sizes and heterogeneous subject composi-
tion, availed themselves of structural and functional neuroim-
aging. The literature on imaging in AD+P has been recently 
reviewed and thoughtfully organized by Murray et al71 who 
separated the studies by methodological approach, including 
computed tomography, magnetic resonance imaging (MRI), 
single-photon emission computed tomography, and [18F]-
fluorodeoxyglucose position emission tomography (PET) 
studies. As the authors highlight, with some variability and 
inconsistency, the preponderance of imaging evidence across 
methodologies implicate the frontal lobes.71 A computed 
tomography study investigating regional brain atrophy in 
AD+P found that subjects with delusions demonstrated fron-
tal and temporal patterns of asymmetric atrophy, compared 
with AD-P subjects.72 MRI studies of AD+P have generally 
implicated the frontal cortex, with both orbitofrontal and 
medial frontal involvement.73,74 PET studies – with only 
one exception75 – have consistently shown frontal hypome-
tabolism in AD+P relative to AD-P.76–80 In an analysis of a 
large, well-controlled sample drawn from the ADNI database, 
we observed a specific relationship between orbitofrontal 
hypometabolism and AD+P.59
Neurotransmission in AD+P
An early theory promulgated in an effort to explain the 
prevalence of psychosis in AD suggested that a preservation 
of dopaminergic tone in the context of early cholinergic defi-
cits may result in a relative “hyperdopaminergic” state, with 
resultant psychosis.81 However evidence for a relative excess 
of dopaminergic tone has been limited. An early postmortem 
study of neurotransmission in psychotic AD did not identify 
any abnormalities in markers of dopamine signaling.82 One 
small postmortem study suggested a selective increase in 
D3 receptor availability.83 Further, using [11C]-raclopride 
PET, a modest increase in tracer binding in the striatum was 
observed in a cohort of delusional patients, suggesting some 
increase in D3 availability.84 Yet, a recent comprehensive 
postmortem study of monoaminergic correlates of behavioral 
symptoms in AD did not observe any relationship between 
alterations in dopamine or dopamine metabolite concentra-
tions in nine behaviorally and neurochemically relevant brain 
regions and psychotic symptoms in AD.85
Perturbations in serotonergic systems have been reported 
in postmortem studies of psychotic AD. A reduction of 
serotonin (5-HT) has been reported in several studies across 
several brain regions,82,86 as have altered 5-HT
6
 recep-
tor function87 and a reduction in cell counts in the dorsal 
raphe nucleus.88 In a recent study, a significant reduction in 
serotonergic tone comprising lower 5-hydroxyindoleacetic 
acid concentrations in the hippocampus and lower 5-HT 
concentrations in the superior temporal gyrus and cerebral 
cortex, correlated with dementia severity.85 It may be that the 
association observed in previous studies between psychosis 
in AD and reduced 5-HT may be related to regional disease 
severity in psychotic AD, and not an independent risk factor 
for the emergence of the syndrome.
Although currently available agents have not achieved 
satisfying rates of success in treating AD+P, continued 
exploration of perturbations in neurotransmitter systems 
in AD+P, together with the advent of more-sophisticated 
supportive therapeutics, may prove helpful in treating this 
condition.
Neuropathology in AD+P:  
a focus on tau
The classical protein pathologies in Alzheimer’s disease 
comprise extracellular amyloid-beta (Aβ) plaques and 
intracellular neurofibrillary tangles, composed primarily 
of hyperphosphorylated tau proteins. As AD+P is a more-
rapidly progressing disease variant, with evidence of some 
localization of disease to the frontal cortex, neuropathologi-
cal correlation studies are critical in the search for disease 
etiology. In general, evidence collected from neuropatho-
logical studies supports an association of AD+P with tau, 
rather than Aβ pathology.44 This is not entirely surprising, 
since in AD distribution of tangle pathology, rather than Aβ 
pathology, correlates most closely with disease severity.89 
Postmortem studies consistently point to a heavier burden 
of tangle pathology in AD+P, with some localization in the 
frontal cortex.82,88,90,91
In order to explore tau pathology in AD+P, our group 
accessed the ADNI database to look for cerebrospinal fluid 
(CSF) evidence of increased tau in AD+P. Previous reports 
have linked elevations of CSF total tau with the postmortem 
burden of neurofibrillary tangles,92,93 so we approached the 
data with the hypothesis that we would find elevations in 
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total tau in AD+P relative to AD-P as a reflection of tangle 
pathology. Indeed, we found that of the three core CSF AD 
biomarkers (Aβ, total tau, phospho-tau), only elevation of 
total tau in CSF was statistically significantly associated 
with psychosis in AD, driven by a robust association in 
females with AD+P.94 In a contemporaneous postmortem 
immunohistochemical study of the frontal cortex conducted 
by colleagues in the laboratory of Dr Robert Sweet, hyper-
phosphorylated tau (the main component of neurofibrillary 
tangles)95 was overabundant in subjects with AD+P com-
pared with AD-P, strengthening the association of AD+P 
with tau.96 
Recently, in collaboration with Dr. Sweet, we conducted 
a biochemical analysis of phospho-tau epitopes in AD+P 
using a high-sensitivity enzyme-linked immunosorbent assay 
(ELISA) developed in the laboratory of Dr Peter Davies.97 
The ELISAs utilize highly specific monoclonal antibodies 
to phospho-tau epitopes that are representative of a range of 
tau pathology, from neuritic to pretangle to mature tangles.98 
Our experiments were conducted on postmortem tissue 
samples from the superior frontal gyri of 71 subjects. As 
α-synuclein pathology is known to contribute to a psychotic 
phenotype in dementia with Lewy bodies (DLB), we con-
trolled for α-synuclein pathology.99 We observed in women 
with AD+P, but not in men with AD+P, a robust association 
with tau pathology.100 In females, while levels of nonpatho-
genic total tau as measured with DA31 antibody ELISA did 
not differ between AD+P and AD-P groups, pathogenic 
phospho-tau species did differ significantly. AD+P females 
had significantly higher levels of phosphorylated tau than 
did AD-P females at each epitope interrogated: Ser396/404 
(PHF-1), Ser202 (CP13), Thr231 (RZ3), and Ser199/202/
Thr205 (AT8). Males with AD+P, all of whom were not 
suffering with clinical DLB prior to death, nonetheless had 
an increase in α-synuclein pathology. In males this sug-
gests that α-synuclein may make a unique contribution to 
AD+P, while in females tau pathology may be the source 
of vulnerability. 
Previously conducted neuropathology studies have 
not been parsed by sex. There is evidence, however, that 
female sex is an independent risk factor for psychosis in 
AD.30,46,101,102 There is some support for biological under-
pinnings of this distinction from imaging studies. An MRI 
study in AD+P evidenced reduced frontotemporal cortical 
thickness in women, rather than in men, with AD+P.74 
Additionally, cerebral perfusion patterns in AD+P have 
been shown to be sex-specific.103 The significance of the sex 
specificity of the association of AD+P with tau pathology 
is not yet clear, and more research is necessary to confirm 
this relationship.
Future directions: a pathology-
guided approach
The published research in AD+P points toward an accelerated 
cognitive decline, with a particular burden of impairment 
affecting performance on frontal tasks. There is strong evi-
dence that degeneration is accelerated in the frontal cortex, 
likely mediated by tau pathology, especially in females. This 
suggests a model of AD+P in which normative temporo–
parietal deficits of AD are complicated by an accelerated 
extension to the frontal cortex. There may be some sex 
specificity to this model, and the degree to which the frontal 
tauopathy of AD+P is a female problem is not yet clear. 
However, the model, in identifying pathogenic proteins and 
localization, does enable translational research that may aid 
in illuminating in just what regions, and to what degree, tau 
pathology may contribute to the psychotic phenotype.
Animal models of psychiatric disease pose a particular 
challenge, in that the core of psychiatric illness is experi-
ence, something inaccessible in observations of animals that 
are language deficient. However, there is a long history of 
observing animals under conditions designed to serve as 
analogues of precipitants of human behavioral disorders and 
of studying physiological changes in these animals; a more 
recent history of observing animals with physiological 
changes known to be associated with human disease and of 
studying behavioral changes. In AD, translational research 
relies to a large degree on the advent of transgenic mice 
carrying autosomal dominant mutations in human genes that 
are known to cause the disease, or to cause pathology associ-
ated with the disease. The mice, depending on the identity 
of the mutation, produce an abundance of Aβ-driven plaque 
or tau-driven neurofibrillary tangle pathology and display 
dense cognitive deficits.104 Curiously, to date, these models 
have only infrequently been employed to study the behav-
ioral syndromes so common in AD. This raises interesting 
questions. Are there outcome measures in mice relevant to 
psychosis that could be utilized in such an exploration? If 
so, could extant mouse models be employed to elucidate 
the neuropathological substrate responsible for AD+P? If 
AD+P in humans emerges, in part, secondary to frontal 
neurodegeneration driven by tau, could a mouse model 
aid in a more-precise localization of the frontal deficits 
responsible?
Currently employed paradigms for modeling psychosis 
in mice include induction of locomotor hyperactivity and 
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disruption of sensorimotor gating, quantified with prepulse 
inhibition (PPI) of acoustic startle.105 Locomotor hyperac-
tivity, as a model of psychosis in rodents resulting from 
exogenous agents promoting dopamine release, is the con-
ceptual offspring of the hyperdopaminergic hypothesis of 
schizophrenia;106 deficits of PPI represent an endophenotype 
of psychosis itself that has been associated with schizophrenia 
and may have broad relevance in all psychotic states.107 PPI 
is defined as the reduction of the intensity of motor startle 
in response to a startle stimulus (for example, acoustic) 
when the stimulus is preceded by a diminished, nonstartle 
stimulus. In a normal state, the startle induced by the startle 
stimulus should be significantly gated by the attention paid 
to the preceding stimulus. In psychosis, this ability to inhibit 
startle is disrupted by a failure of normal gaiting, perhaps 
representing a diminished capacity to monitor environmental 
stimuli appropriately.108 PPI of acoustic startle as a phenotypic 
marker of psychosis may be best described as “the interface 
of psychosis and cognition,”105,109 representing a cognitive 
failure that potentially influences environmental surveillance 
and may promote psychotic misinterpretation. The confluence 
of cognitive impairment and environmental misapprehension 
implicit in PPI deficiency makes PPI an attractive outcome 
measure in investigating potential animal models of AD+P.
In order to develop a preclinical mouse model of AD+P, 
we recently selected an AD model manifesting early frontal 
tauopathy, the transgenic rTg(tau
P301L
)4510 mouse,110 and 
characterized PPI deficits over time in relationship to tau 
pathology.111 We demonstrated that PPI deficits accrued over 
time in female rTg(tau
P301L
)4510 mice, and that these deficits 
were driven by the same pathogenic hyperphosphorylated 
tau molecules that we had previously observed in the frontal 
cortex of human female AD+P subjects.100 This suggests that 
the rTg(tau
P301L
)4510 mouse may be a candidate for preclini-
cal study of AD+P biology and the development of novel 
therapeutics. There is more work to be done prior to settling 
on any animal model of AD+P. Future studies involving this 
model will include expanding the phenotypic characteriza-
tion of this mouse beyond PPI to include other cognitive 
and behavioral markers of psychosis, and exploring the sex 
specificity of the observed behavioral characteristics.
The way forward in the treatment of AD+P may tran-
scend traditional psychiatric treatments of psychosis and 
may involve the reduction of pathogenic proteins rather 
than supporting aberrant neurotransmitter systems that are 
the downstream effects of disease pathology. Future treat-
ments may focus on tau pathology, α-synuclein pathology, 
or both. Several tau reduction agents are currently in the drug 
development stage for the treatment of AD, and even if they 
do not provide a cure for the primary illness, they warrant 
exploration in the service of combating a particularly morbid 
and common manifestation of the disease.
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